- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Giuseppe Saglio Compares Efficacy, Safety of Nilotinib With Imatinib for CML Patients
Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib's side effects are too much for patients.
Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib’s side effects are too much for patients, according to a study from Novartis presented at the 56th Annual Meeting of the American Society of Hematology.
Giuseppe Saglio, MD, one of the co-authors on the study and a professor of internal medicine at the University of Turin in Italy, explained that while just 10% of patients who stopped imatinib did so because of side effects, 20% of patients on nilotinib stopped treatment because of side effects.
“So I think, probably, we have to reconsider all this data to suggest which is the best appropriate treatment and particular dosage of the drug as first-line therapy,” Dr Saglio said.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
